Epirus, Ranbaxy deal

Epirus granted Ranbaxy rights to commercialize BOW015 in India and undisclosed markets in Southeast Asia and North Africa. BOW015 is a biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). Epirus will receive an undisclosed upfront payment and is eligible for milestones, plus royalties. Epirus submitted a regulatory application for BOW015 in India in November and said it will submit applications in "targeted emerging markets" over the next 12 months. Ranbaxy is a subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568, Tokyo, Japan). ...